Resistance to 5FU or oxaliplatin correlates with the upregulation of REV7 and high TLS efficiency in colon cancer cells [102], and REV7 inactivation overcomes acquired resistance to cisplatin in TGCT cells and to 5FU and oxaliplatin in colon cancer cells in vitro and in vivo [91,102]. Here, MAD2L2 is linked to malignant colon neoplasm.